ABOUT THE PRODUCT
SCY-770 is a novel, highly selective, clinical-stage direct AMPK activator under development as a new therapeutic approach for Autosomal Dominant Polycystic Kidney Disease (ADPKD). It directly activates AMPK, a key regulator of cellular metabolism, addressing the disease’s underlying metabolic abnormalities.
Information is owner-confirmed
Last updated 6 days ago
Price range
Other products/services from SCYNEXIS, Inc.
SCY-247
Biotechnology
N/A
SCYNEXIS, Inc.
United States (US)